Navigation Links
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
Date:6/8/2008

Oral presentation at international lymphoma conference shows investigational regimen resulted in 82 percent overall survival and 78

percent progression-free survival rates in patients receiving

radioimmunotherapy Confirmatory phase III clinical trial is presently being conducted in this

patient population

LUGANO, Switzerland, June 9 /PRNewswire-FirstCall/ -- In an oral presentation today at the 10th International Conference on Malignant Lymphoma in Lugano, Switzerland, Paul A. Hamlin, M.D., of Memorial Sloan-Kettering Cancer Center, presented results of an investigator-sponsored trial of the investigational regimen consolidating rituximab-CHOP (R-CHOP) with 90Yttrium Ibritumomab Tiuxetan (Zevalin(R)) radioimmunotherapy in high risk, elderly patients with previously untreated high-intermediate and high risk diffuse large B-cell lymphoma (DLBCL). Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) markets Zevalin in the United States.

"In a high risk, elderly patient population with significant comorbidities, sequential R-CHOP followed by radioimmunotherapy resulted in excellent complete response and overall and progression-free survival rates," concluded Hamlin. "This approach is now the focus of an international phase III study."

"Improvement of relapse-free survival in these patients is an important unmet need since the outcome is poor for patients who relapse with this disease and who cannot tolerate intensive salvage therapy and stem cell transplantation," said Jack W. Singer, M.D., Chief Medical Officer at CTI. "The survival data from this study are highly encouraging compared to historical data and provide the rationale for a registration-directed randomized trial of Zevalin consolidation in higher risk patients with DLBCL."

Results of the Study

Historical studies provided as background in the presentation indicate that approximately 50 perc
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
2. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
3. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
4. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
5. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
6. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
7. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
8. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
9. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 6, 2015 Mauna Kea ... multidisciplinary confocal laser endomicroscopy platform, announced today it ... Ministry of Health, Labor and Welfare (MHLW) ... the AQ-Flex 19 miniprobe.   Used ... miniprobe is comprised of a fiber-optic microscope that ...
(Date:7/6/2015)... 6, 2015   BioClinica®, Inc ., a ... announced that it has acquired a leading global ... Inc. (Medici).  The acquisition includes affiliates MediciGlobal ... also provides a lost-to-follow-up patient locate service ( ... with Medici, BioClinica will offer pharmaceutical ...
(Date:7/6/2015)... DUBLIN, Ohio , July 6, 2015 ... of The Harvard Drug Group (THDG). A distributor of generic ... and alternate care customers, THDG was owned by Court ... all-cash transaction using existing cash and new debt.  ... , The Harvard Drug Group had revenues of approximately ...
Breaking Medicine Technology:Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 3BioClinica Acquires MediciGroup 2BioClinica Acquires MediciGroup 3Cardinal Health Completes Acquisition Of The Harvard Drug Group For $1.115 Billion 2Cardinal Health Completes Acquisition Of The Harvard Drug Group For $1.115 Billion 3
... May 10th, 2007 - Antisense,Pharma, a German biopharmaceutical ... announced, that data from the,Phase IIb-study with AP ... 43rd Annual Meeting of the American Society of,Clinical ... Illinois,U.S.A, from June 1st - 5th. , In ...
... NICE Appraisal Committee concludes that alteplase is clinically,and ... 2007 – A new clinical appraisal,published by the ... the UK has recommended the use of alteplase,for ... based on,its clinical and cost effectiveness compared with ...
Cached Medicine Technology:2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 22007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 3Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 2Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 3Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 4Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 5
(Date:7/6/2015)... ... 2015 , ... Cancer Hope Network (CHN) has relaunched their ... to chat with the CHN patient services team and connect with a Support ... often the most traumatic experience of a person’s life,” said CHN Executive Director, ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... MD Now, ... Monday, July 6. The newly constructed urgent care center will serve residents and visitors ... In addition to being MD Now’s 22nd South Florida location, the new facility will ...
(Date:7/6/2015)... ... July 06, 2015 , ... World renowned Los Angeles facial plastic surgeon ... appearance through comprehensive treatment solutions. Individuals that want to make multiple changes to their ... plan that resolves each of their needs. , "Anytime I see an opportunity ...
(Date:7/6/2015)... ... July 06, 2015 , ... Diabetes affects many of ... than 29 million Americans have diabetes, the majority of which are Type 2. However, ... or more than one in three, have prediabetes (abnormally high blood sugar levels). Without ...
(Date:7/5/2015)... ... July 06, 2015 , ... City Sports, the Boston-based ... will co-produce two training clinics for first-time triathletes this summer with ethos, the owner ... place on Thursday, July 9, at 6:00 p.m. at the North End Greenway. The ...
Breaking Medicine News(10 mins):Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 2Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 3Health News:Los Angeles Plastic Surgeon, Dr. Paul Nassif, is Now Offering Comprehensive Facial Plastic Surgery Procedures 2Health News:115 Million in the U.S. could beat diabetes with the help of a new app 2Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 2Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 3
... VILLAGE, Calif., Jan. 6 Specialists On Call, ... the states in which it provides service, including ... provider of emergency neurology on-call services to hospitals, ... consultations to date.(Logo: http://www.newscom.com/cgi-bin/prnh/20081022/LAW515LOGO )Dr. Joe ...
... OF PRUSSIA, Pa., Jan. 6 Prism Pharmaceuticals, Inc.,announced ... Executive,Officer, will present at the 27th Annual J.P. Morgan ... (Pacific Time) or 10:30 a.m. (Eastern,Time). The conference ... in San,Francisco, California. , Dr. ...
... Inc. (NYSE: WLP ), the,nation,s largest ... today the expansion of its innovative disease management ... members in its affiliated health,plans suffering from Bipolar ... each year. The Bipolar Condition Care Program will ...
... Specialists On Call, Inc. (SOC) announced today that ... provides service, including California. SOC is the ... to hospitals, having already managed more than 5,500 ... )Dr. Joe Peterson, CEO, described the company,s ongoing ...
... Therapeutics, Inc.,(Nasdaq: OREX ), a biopharmaceutical company ... Company will be speaking at the 27th Annual,J.P. Morgan ... Date: Monday, January 12, 2009, ... a.m. Pacific, Location: Westin St. Francis, ...
... in "CVS/pharmacy dollars" throughout the last quarter of ... easy for consumers to save money WOONSOCKET, R.I., ... today announced that ExtraCare cardholders received more than ... 2008, simply by using their ExtraCare card when ...
Cached Medicine News:Health News:Specialists On Call Expands Access to Emergency Neurology On-Call Services in North Carolina 2Health News:WellPoint Announces Innovative Program to Help Improve the Care of Members Suffering With Bipolar Disorder 2Health News:WellPoint Announces Innovative Program to Help Improve the Care of Members Suffering With Bipolar Disorder 3Health News:Specialists On Call Expands Access to Emergency Neurology On-Call Services in California 2Health News:CVS/pharmacy Offers Shoppers More Than $69 Million in 'Extra Bucks' 2Health News:CVS/pharmacy Offers Shoppers More Than $69 Million in 'Extra Bucks' 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: